LONDON, May 15 (Reuters) - AstraZeneca (AZN.L: Quote, Profile, Research) is to buy Cambridge Antibody Technology (CAT) in a deal valuing CAT at 702 million pounds ($1.3 billion), extending a drive into biological medicines as it looks to restock a depleted drugs pipeline.
